Brandon Capital, Australasia’s leading life science venture capital firm, is pleased to announce its investment into neuroscience company NRG Therapeutics as part of its £16m (AUD$29m) series A financing.
Brandon Capital participated alongside Omega Funds, which led the round, as well as NRG’s founding investor, Parkinson’s Virtual Biotech. This is Brandon’s second investment in the UK since opening its London office in 2021, following its recently announced investment in Pheon Therapeutics.
NRG is applying breakthrough science in the field of mitochondrial biology to develop disease-modifying therapeutics to slow or halt the progression of neurodegenerative disorders such as Parkinson’s and ALS (also known as motor neurone disease or MND). The Series A proceeds will be used to advance the company’s potential first-in-class brain-penetrant small molecules through IND-enabling studies.
NRG is targeting a novel pathological mechanism in ALS that was identified by Professor Seth Masters, Ph.D., at Australia’s WEHI (Walter and Eliza Hall Institute of Medical Research), a Brandon BioCatalyst member institute. Specifically, NRG’s approach is based on inhibiting a novel protein within the mitochondrial permeability transition pore (mPTP) in neurons, which has been shown to be neuroprotective in several preclinical models of Parkinson’s and ALS. It was Professor Masters who showed that the mPTP is involved in the pathology of ALS1. NRG has an ongoing Research Collaboration Agreement with WEHI to further drug discovery based on these pioneering studies funded by a Drug Development grant awarded to WEHI from FightMND, under which NRG is the Industrial Partner.
Following the financing, Professor Masters has joined the NRG management team as VP of Discovery Biology. His laboratory at WEHI in Melbourne, Australia, will also include a sponsored team as part of an expanded research agreement between NRG and WEHI.
Jonathan Tobin, Partner at Brandon Capital said, “We are delighted to add NRG Therapeutics to our growing European portfolio. Brandon Capital was attracted to the company by its first-in-class mechanism that could make a major difference to patients with devastating neurodegenerative diseases, combined with the seasoned management team that Brandon has backed previously.
“Given Brandon Capital’s heritage in Australia we have a unique advantage in bringing insights and opportunities to our portfolio companies through access to the world-class science in Australia and its favorable environment for clinical development. We are delighted to see the collaboration between NRG and WEHI, with Professor Seth Masters further strengthening the NRG team.”
Professor Seth Masters, VP of Discovery Biology at NRG Therapeutics and Laboratory Head, Inflammation Division at WEHI, said: “I am excited to be joining the NRG team alongside leading my group at WEHI. We were the first to identify a novel mechanism by which neuroinflammation is triggered in TDP-43 proteinopathies. Our assessment of cell lines, a mutant TDP-43 model, and human ALS-affected spinal cord samples provides support for a model where TDP-43 liberates mtDNA into the cytoplasm via the mPTP to activate cGAS/STING signaling. I look forward to exploring with NRG whether targeting this pathway with its novel mPTP inhibitors can improve the symptoms of neuronal decline in patients with disease involving TDP-43 proteinopathy, such as ALS.”
NRG Therapeutics’ co-founder and CEO Dr Neil Miller said, “We are delighted to welcome Omega Funds and Brandon Capital as new investors and thank Parkinson’s Virtual Biotech for its continued support. We look forward to working with them, and our expanding team and R&D partners to bring new medicines and hope to the growing number of people worldwide living with debilitating neurological diseases.”
Parkinson’s affects ~10 million individuals worldwide and is the fastest-growing neurological disorder in the world, presenting a major healthcare challenge for society. ALS is a rare fatal neurodegenerative disorder that typically leads to death within 3-5 years of diagnosis. The marketed disease-modifying treatments for ALS provide an extension in survival of approximately 3-6 months. Given this extension in life is modest and patients are hugely debilitated in the terminal phase disease, an improved disease-modifying medicine is desperately needed.
For further information, please contact:
Brandon Capital (media enquiries)
Sue Charles, Charles Consultants
Tel: +44 (0)7968 726585
Ciara Byrne, Mana Communications
Tel: +61 (0)41 3519 430
Notes to Editors
About Brandon Capital – www.brandoncapital.vc
Brandon Capital is Australasia’s leading life science venture capital firm, with an international presence and team members across the US and UK. From early-stage seed investment through to expansion capital, Brandon Capital supports life science companies from proof-of-concept through to commercialisation. Our venture model is unique: we don’t just provide investment, we partner with inventors, entrepreneurs and research organisations, providing hands-on support and expertise to increase their chance of success.
Brandon BioCatalyst, Brandon Capital’s Australasian-based collaboration, brings together 50 trans-Tasman medical research institutes, investors, and governments all united in progressing the next generation of medical therapies and technology. Brandon BioCatalyst supports the development and commercialisation of early-stage biomedical discoveries associated with member research organisations, providing both capital and expertise to guide the successful development of new therapies.
About NRG Therapeutics – http://www.nrgtherapeutics.com
NRG Therapeutics is a neuroscience drug discovery company building a pipeline of disease-modifying mitochondrial therapeutics to slow or halt the progression of neurodegenerative disorders such as Parkinson’s and Amyotrophic Lateral Sclerosis (ALS), also known as motor neurone disease (MND).
The company’s pre-clinical pipeline of small molecule assets is based on inhibiting the mitochondrial permeability transition pore (mPTP) through a novel mechanism of action. Inhibition of the mPTP has been shown to protect neurons, reduce neuroinflammation and extend survival in pre-clinical disease models.
Based at the Stevenage Bioscience Catalyst (SBC), UK, NRG Therapeutics is a private company with equity investment from Parkinson’s UK, Omega Funds and Brandon Capital. The company has also received grant funding from The Michael J. Fox Foundation, Innovate UK (Biomedical Catalyst Award), and is the industrial partner for a FightMND Drug Discovery grant awarded to the Walter and Eliza Hall Institute (WEHI).
About WEHI (Walter and Eliza Hall Institute of Medical Research) – www.wehi.edu.au
WEHI is where the world’s brightest minds collaborate and innovate to make life-changing scientific discoveries that help people live healthier for longer. Our medical researchers have been serving the community for more than 100 years, making transformative discoveries in cancers, infectious and immune diseases, developmental disorders, and healthy ageing.
WEHI brings together diverse and creative people with different experience and expertise to solve some of the world’s most complex health problems. With partners across science, health, government, industry, and philanthropy, we are committed to long-term discovery, collaboration, and translation. At WEHI, we are brighter together.
About FightMND – https://fightmnd.org.au/
Founded in 2014, FightMND was established in Australia with the purpose of finding effective treatments and ultimately a cure for Motor Neurone Disease (MND), also referred to as ALS or Lou Gehrig’s Disease. FightMND, with its vision of a world without MND, is the largest independent funder of MND research in Australia. Since 2014, FightMND has investment more than $63 million into MND research and care equipment to improve the lives of those fighting the disease. FightMND is determined to help facilitate the translation of the growing body of new knowledge about the disease into a cure for MND patients in Australia and abroad.